ENTOD Pharmaceuticals, a leader in the eye care pharmaceutical sector, has recorded exceptional market growth, solidifying its position in the ophthalmological and ENT (ear, nose, throat) medicine segments.

The latest September 2024 IQVIA market data reported a challenging period for the ophthalmological and otological sectors, which grew by just 1% annually. Defying industry trends, ENTOD Pharmaceuticals achieved an outstanding 8% growth, demonstrating its resilience and market strength.

The Pharmarack AWACS market data, on the other hand, showed resurgence in this sector in the month of October, with a robust 9.5% value growth. ENTOD Pharmaceuticals once again outperformed the market, achieving a phenomenal 22% growth in October, over twice the industry average.

“Our exceptional market growth reflects ENTOD’s commitment to delivering innovative and accessible solutions in eye care and ENT treatments. Despite industry-wide challenges, our focus on research-driven therapies, expanded reach in underserved areas, and bespoke campaigns for eye health awareness have been pivotal in driving this success. By addressing pressing issues such as myopia in children and glaucoma through progressive treatments and awareness initiatives, we are not only setting benchmarks in market performance but also strengthening our mission to elevate the standard of eye care across India and beyond,” said Nikkhil K Masurkar, CEO, ENTOD Pharmaceuticals.

Milton Jose, Vice President-Sales at ENTOD Pharmaceuticals, attributes this achievement to a combination of factors. These include enhanced performance in North India, significant sales driven by innovative treatments for chronic eye conditions, and a strategic focus on improving productivity per medical representative. He also highlighted the broader sales coverage, which extends from metropolitan hubs to rural areas, as well as the launch of new prescription medicines, as critical contributors to the company’s sustained momentum.

ENTOD Pharmaceuticals boasts 1,200+ medical representatives actively promoting over 300 medicines in India, a global footprint across 67 countries, with its international business growing at a staggering 60% annually, and an advanced R&D pipeline focused on therapeutic advancements for myopia in children, glaucoma, corneal diseases, and retinal conditions.